TTP Group Enhances Exyte’s Position in Europe’s Pharmaceutical Market
Exyte, a global leader in designing, engineering, and delivering high-tech facilities, has announced its intention to acquire TTP Group (“TTP”), a leading consulting and engineering firm in the pharmaceutical and chemical industries across Europe. The acquisition aims to accelerate Exyte’s growth in the biopharma and life sciences sectors by integrating TTP’s extensive engineering expertise into its existing operations.
TTP Group, operating under its two brands ‘Pharmaplan’ and ‘Triplan,’ provides a comprehensive array of engineering services, ranging from feasibility studies and construction management to validation and commissioning. The firm is renowned for its reliable partnerships with leading clients in the biotechnology and pharmaceutical sectors. Exyte’s acquisition of TTP will reinforce its presence in the European market, expanding its capability to serve the growing biotechnology and pharmaceutical sectors.
Dr. Wolfgang Büchele, CEO of Exyte, commented, “The acquisition of TTP enables Exyte to further strengthen its position as a global leader in the pharmaceutical industry. By combining our project execution capabilities with TTP’s engineering expertise, we will create a strong partner for the rapidly growing biotech and pharmaceutical sectors across Europe. This partnership allows us to offer our clients a comprehensive range of services, from strategic planning to facility delivery.”
TTP Group operates across 27 locations in Europe, including Austria, Belgium, France, Germany, and Switzerland. The firm’s team of 1,000 specialists delivered sales of approximately €170 million in 2023. In the coming years, TTP is expected to continue its trajectory of strong and profitable growth, supported by its experienced engineers, architects, and project managers.
Creating Sustainable Solutions for a Growing Industry
The pharmaceutical industry is experiencing significant growth, driven by megatrends such as population ageing, demand for new medical treatments, and technological advancements like mRNA therapies. These factors have increased the need for new manufacturing facilities and upgrades to existing ones. Additionally, sustainability requirements are pushing companies to invest in greener solutions, with digital innovations and flexible production models playing a crucial role in future developments.
“TTP’s operational expertise and innovation in facility engineering, combined with Exyte’s project delivery excellence, will create a unique partnership that can meet the increasing demands of the biopharma industry,” added Büchele. “Our collaboration is a testament to our commitment to delivering high-quality, sustainable solutions that enhance health and wellbeing.”
Dr. Andreas Bonhoff, CEO of TTP Group, stated, “Both TTP and Exyte share a vision for delivering cutting-edge, sustainable solutions to our clients. By joining forces, we’re poised to make even greater strides in the pharmaceutical facilities market. We are excited to embark on this journey together.”
Strategic Growth in Biopharma and Life Sciences
Exyte’s Biopharma and Life Sciences division ranks as the company’s second-largest segment, achieving €580 million in revenue for 2023. With a 12% increase in order intake to €650 million, the addition of TTP is anticipated to further drive Exyte’s success and growth in this sector. As part of its strategic “Next Level” agenda, Exyte aims to exceed €1.5 billion in revenue from this business segment over the next few years.
The company recently completed the construction of the fastest greenfield drug substance facility, taking less than 22 months from concept to production in its mRNA competence centre in Germany. The addition of TTP’s expertise will allow Exyte to continue delivering state-of-the-art pharmaceutical facilities and support the global demand for innovative healthcare solutions.
Ronan Donohue, President of Exyte’s Global Business Unit Biopharma and Life Sciences, highlighted the importance of the acquisition: “The partnership with TTP reinforces our commitment to the biopharma sector. Together, we will continue to deliver advanced, high-tech facilities that support the development of groundbreaking therapies and improve global health outcomes.”
